JACC:经导管治疗上静脉窦型房间隔缺损安全可行

2020-03-20 MedSci原创 MedSci原创

上静脉窦型房间隔缺损(SVASD)的特点是上静脉窦(SVC)与右上肺静脉(RUPV)之间的共同间隔缺失。本研究的目的旨在通过在SVC内植入覆膜支架来评估将SVC和RUPV血流分别转向右心房和左心房的可

上静脉窦型房间隔缺损(SVASD)的特点是上静脉窦(SVC)与右上肺静脉(RUPV)之间的共同间隔缺失。本研究的目的旨在通过在SVC内植入覆膜支架来评估将SVC和RUPV血流分别转向右心房和左心房的可能性。

本研究纳入分析了48例SVASD成年患者,其中25例接受了经导管纠治术,还有6个在等待支架植入,只有8名患者被认为在技术上不合适。植入支架的长度在5-8cm之间,有9名患者接受了二次裸支架植入,有4名患者为防止肺静脉梗阻在支架植入过程中在右上肺静脉加入了高压球囊。经过平均1.4年时间的随访,没有死亡病例发生。1名患者发生支架内血栓形成,1名患者出现心包积血。

研究结果显示,对于上静脉窦型房间隔缺损患者,经导管纠治术是外科手术外的一个替代治疗选择。

原始出处:

Jan H et al.Transcatheter Correction of Superior Sinus Venosus Atrial Septal Defects as an Alternative to Surgical Treatment.JACC.2020 Mar.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-04-15 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2021-03-04 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-03-22 lsj631
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854697, encodeId=4ac0185469ea0, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Apr 15 09:04:09 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698059, encodeId=fcd4169805953, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Mar 04 11:04:09 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326529, encodeId=a3ec13265295b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459431, encodeId=5af01459431b1, content=<a href='/topic/show?id=0820542427d' target=_blank style='color:#2F92EE;'>#房间隔缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54242, encryptionId=0820542427d, topicName=房间隔缺损)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510287, encodeId=d8b6151028e4d, content=<a href='/topic/show?id=e9bce8254ef' target=_blank style='color:#2F92EE;'>#经导管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78254, encryptionId=e9bce8254ef, topicName=经导管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e010191378, createdName=lsj631, createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618557, encodeId=5605161855e71, content=<a href='/topic/show?id=a95e9916698' target=_blank style='color:#2F92EE;'>#静脉窦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99166, encryptionId=a95e9916698, topicName=静脉窦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=237819898930, createdName=12498d2fm57(暂无昵称), createdTime=Sun Mar 22 11:04:09 CST 2020, time=2020-03-22, status=1, ipAttribution=)]

相关资讯

JACC:二甲双胍可以减少心脏移植糖尿病患者的脂质沉积

糖尿病心肌病(DMCM)的早期发病机制可能与高血糖背景下心肌细胞的脂质毒性有关。本研究以糖尿病(DM)患者的非糖尿病(non-DM)心脏移植(HTX)为研究对象,对人类心脏移植受者进行了一系列的研究,

BMJ:这么吃,心血管疾病和死亡风险更低

吃是一种需要,会吃却是一门学问。合理的饮食结构、适当的营养元素搭配,可以增加抵御疾病的能力,并降低肥胖、心血管疾病等非传染性疾病的患病风险。那么,如何吃更健康呢?

JACC:干细胞治疗肌营养不良的实验研究

尽管心肌病已经成为Duchenne肌营养不良(DMD)的主要死因,但是目前尚无有效治疗手段。本研究的目的旨在利用DMD患者特异性人诱导多能干细胞(hiPSC)来源的心肌细胞来探究可能的药物治疗手段。

盘点:JACC3月第三期研究一览

1. 即时高敏肌钙蛋白检测试剂盒对疑似心梗具有较好的诊断价

JACC:阿哌沙班剂量调整对药理学和临床预后的影响

本研究的目的是描述阿哌沙班剂量调整对临床和药理学结果的影响。

JACC:liraglutide对2型糖尿病患者心血管的影响

本研究的目的旨在评估胰高血糖素样肽-1受体激动剂liraglutide对LEADER临床试验中患者的心血管事件发生和死亡率的影响。